|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SSFA2 |
Gene summary for SSFA2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SSFA2 | Gene ID | 6744 |
| Gene name | ITPR interacting domain containing 2 | |
| Gene Alias | CS-1 | |
| Cytomap | 2q31.3 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | P28290 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6744 | SSFA2 | GSM4909296 | Human | Breast | IDC | 6.79e-05 | -1.61e-01 | 0.1524 |
| 6744 | SSFA2 | GSM4909297 | Human | Breast | IDC | 7.73e-03 | -1.13e-01 | 0.1517 |
| 6744 | SSFA2 | GSM4909299 | Human | Breast | IDC | 4.14e-05 | 3.51e-01 | 0.035 |
| 6744 | SSFA2 | GSM4909307 | Human | Breast | IDC | 1.54e-20 | 6.89e-01 | 0.1569 |
| 6744 | SSFA2 | GSM4909308 | Human | Breast | IDC | 2.92e-50 | 8.73e-01 | 0.158 |
| 6744 | SSFA2 | GSM4909311 | Human | Breast | IDC | 2.45e-07 | -1.65e-01 | 0.1534 |
| 6744 | SSFA2 | GSM4909313 | Human | Breast | IDC | 1.03e-02 | 2.74e-01 | 0.0391 |
| 6744 | SSFA2 | GSM4909319 | Human | Breast | IDC | 1.04e-08 | -1.95e-01 | 0.1563 |
| 6744 | SSFA2 | GSM4909321 | Human | Breast | IDC | 2.13e-05 | -1.65e-01 | 0.1559 |
| 6744 | SSFA2 | M5 | Human | Breast | IDC | 6.05e-08 | 7.13e-01 | 0.1598 |
| 6744 | SSFA2 | P1 | Human | Breast | IDC | 4.22e-02 | -1.26e-01 | 0.1527 |
| 6744 | SSFA2 | DCIS2 | Human | Breast | DCIS | 3.10e-65 | 5.07e-01 | 0.0085 |
| 6744 | SSFA2 | HTA11_3410_2000001011 | Human | Colorectum | AD | 7.47e-34 | -6.13e-01 | 0.0155 |
| 6744 | SSFA2 | HTA11_2487_2000001011 | Human | Colorectum | SER | 1.51e-20 | -6.13e-01 | -0.1808 |
| 6744 | SSFA2 | HTA11_2951_2000001011 | Human | Colorectum | AD | 6.69e-05 | -6.13e-01 | 0.0216 |
| 6744 | SSFA2 | HTA11_1938_2000001011 | Human | Colorectum | AD | 8.06e-16 | -6.13e-01 | -0.0811 |
| 6744 | SSFA2 | HTA11_78_2000001011 | Human | Colorectum | AD | 5.25e-24 | -6.13e-01 | -0.1088 |
| 6744 | SSFA2 | HTA11_347_2000001011 | Human | Colorectum | AD | 3.11e-36 | -6.13e-01 | -0.1954 |
| 6744 | SSFA2 | HTA11_411_2000001011 | Human | Colorectum | SER | 7.73e-03 | -6.13e-01 | -0.2602 |
| 6744 | SSFA2 | HTA11_2112_2000001011 | Human | Colorectum | SER | 3.67e-04 | -6.13e-01 | -0.2196 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SSFA2 | SNV | Missense_Mutation | c.3652N>A | p.Glu1218Lys | p.E1218K | P28290 | protein_coding | deleterious(0.01) | probably_damaging(0.994) | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| SSFA2 | SNV | Missense_Mutation | c.558N>G | p.Asn186Lys | p.N186K | P28290 | protein_coding | deleterious(0) | probably_damaging(0.983) | TCGA-A2-A1FV-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cyclophosphamide | SD | |
| SSFA2 | SNV | Missense_Mutation | c.839N>A | p.Thr280Lys | p.T280K | P28290 | protein_coding | tolerated(0.07) | benign(0.202) | TCGA-A2-A25B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | PD | |
| SSFA2 | SNV | Missense_Mutation | c.2525N>G | p.Ser842Cys | p.S842C | P28290 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| SSFA2 | SNV | Missense_Mutation | novel | c.2720N>T | p.Ser907Leu | p.S907L | P28290 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AC-A3W6-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| SSFA2 | SNV | Missense_Mutation | novel | c.998N>C | p.Glu333Ala | p.E333A | P28290 | protein_coding | deleterious(0.01) | possibly_damaging(0.721) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SSFA2 | SNV | Missense_Mutation | c.618N>A | p.Asn206Lys | p.N206K | P28290 | protein_coding | deleterious(0) | possibly_damaging(0.725) | TCGA-AR-A24Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| SSFA2 | SNV | Missense_Mutation | novel | c.619N>C | p.Ser207Pro | p.S207P | P28290 | protein_coding | deleterious(0) | probably_damaging(0.974) | TCGA-AR-A24Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| SSFA2 | SNV | Missense_Mutation | c.2587N>G | p.Arg863Gly | p.R863G | P28290 | protein_coding | deleterious(0.01) | probably_damaging(0.983) | TCGA-BH-A0DV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | CR | |
| SSFA2 | SNV | Missense_Mutation | c.2775N>T | p.Gln925His | p.Q925H | P28290 | protein_coding | tolerated(0.06) | probably_damaging(0.997) | TCGA-BH-A1FU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |